$TIVC
Tivic Health Systems, Inc.

2024 Q4 Form 10-Q Financial Statement

#000095017024127072 Filed on November 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3 2023 Q3
Revenue $126.0K $282.0K
YoY Change -55.32% -40.88%
Cost Of Revenue $82.00K $174.0K
YoY Change -52.87% -57.97%
Gross Profit $44.00K $108.0K
YoY Change -59.26% 71.43%
Gross Profit Margin 34.92% 38.3%
Selling, General & Admin $1.053M $1.531M
YoY Change -31.22% -31.9%
% of Gross Profit 2393.18% 1417.59%
Research & Development $422.0K $337.0K
YoY Change 25.22% -15.54%
% of Gross Profit 959.09% 312.04%
Depreciation & Amortization $1.000K -$4.000K
YoY Change -125.0% -233.33%
% of Gross Profit 2.27% -3.7%
Operating Expenses $1.475M $1.868M
YoY Change -21.04% -29.43%
Operating Profit -$1.431M -$1.760M
YoY Change -18.69% -31.89%
Interest Expense $0.00
YoY Change -100.0%
% of Operating Profit
Other Income/Expense, Net $0.00
YoY Change
Pretax Income -$1.760M
YoY Change -31.89%
Income Tax
% Of Pretax Income
Net Earnings -$1.431M -$1.760M
YoY Change -18.69% -32.31%
Net Earnings / Revenue -1135.71% -624.11%
Basic Earnings Per Share -$0.23 -$1.48
Diluted Earnings Per Share -$0.23 -$1.48
COMMON SHARES
Basic Shares Outstanding 8.266M 6.184M 146.6M
Diluted Shares Outstanding 6.191M 1.190M

Balance Sheet

Concept 2024 Q4 2024 Q3 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $5.169M
YoY Change -18.32%
Cash & Equivalents $2.200M $5.200M
Short-Term Investments
Other Short-Term Assets $227.0K
YoY Change -44.63%
Inventory $731.0K $928.0K
Prepaid Expenses
Receivables $9.000K $131.0K
Other Receivables $0.00
Total Short-Term Assets $3.163M $6.455M
YoY Change -51.0% -15.0%
LONG-TERM ASSETS
Property, Plant & Equipment $119.0K $124.0K
YoY Change -4.03% 726.67%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $34.00K
YoY Change 0.0%
Total Long-Term Assets $231.0K $552.0K
YoY Change -58.15% -10.1%
TOTAL ASSETS
Total Short-Term Assets $3.163M $6.455M
Total Long-Term Assets $231.0K $552.0K
Total Assets $3.394M $7.007M
YoY Change -51.56% -14.63%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $333.0K $638.0K
YoY Change -47.81% -60.17%
Accrued Expenses $362.0K
YoY Change -14.01%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $560.0K $1.000M
YoY Change -44.0% -50.57%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $242.0K
YoY Change -41.4%
Total Long-Term Liabilities $242.0K
YoY Change -41.4%
TOTAL LIABILITIES
Total Short-Term Liabilities $560.0K $1.000M
Total Long-Term Liabilities $242.0K
Total Liabilities $560.0K $1.242M
YoY Change -54.91% -49.01%
SHAREHOLDERS EQUITY
Retained Earnings -$42.10M -$35.60M
YoY Change 18.26% 29.93%
Common Stock $1.000K $0.00
YoY Change -100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $2.834M $5.765M
YoY Change
Total Liabilities & Shareholders Equity $3.394M $7.007M
YoY Change -51.56% -14.63%

Cashflow Statement

Concept 2024 Q4 2024 Q3 2023 Q3
OPERATING ACTIVITIES
Net Income -$1.431M -$1.760M
YoY Change -18.69% -32.31%
Depreciation, Depletion And Amortization $1.000K -$4.000K
YoY Change -125.0% -233.33%
Cash From Operating Activities -$1.867M
YoY Change -32.65%
INVESTING ACTIVITIES
Capital Expenditures -$2.000K
YoY Change -60.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $2.000K
YoY Change -140.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.377M
YoY Change 7716.07%
NET CHANGE
Cash From Operating Activities -1.867M
Cash From Investing Activities 2.000K
Cash From Financing Activities 4.377M
Net Change In Cash 2.512M
YoY Change -192.32%
FREE CASH FLOW
Cash From Operating Activities -$1.867M
Capital Expenditures -$2.000K
Free Cash Flow -$1.865M
YoY Change -32.6%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001787740
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.01
CY2023Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.01
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-41052
dei Entity Registrant Name
EntityRegistrantName
Tivic Health Systems, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
81-4016391
dei Entity Address Address Line1
EntityAddressAddressLine1
47685 Lakeview Blvd
dei Entity Address City Or Town
EntityAddressCityOrTown
Fremont
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94538
dei City Area Code
CityAreaCode
888
dei Local Phone Number
LocalPhoneNumber
276-6888
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
TIVC
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
8266085
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2189000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3395000
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
9000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
174000
CY2024Q3 us-gaap Inventory Net
InventoryNet
731000
CY2023Q4 us-gaap Inventory Net
InventoryNet
756000
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
234000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
327000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
3163000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
4652000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
119000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
122000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
349000
CY2024Q3 tivc Deferred Offering Costs Noncurrent
DeferredOfferingCostsNoncurrent
112000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
34000
CY2024Q3 us-gaap Assets
Assets
3394000
CY2023Q4 us-gaap Assets
Assets
5157000
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
333000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
713000
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
227000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
495000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
193000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
560000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1401000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
176000
CY2024Q3 us-gaap Liabilities
Liabilities
560000
CY2023Q4 us-gaap Liabilities
Liabilities
1577000
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6243403
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6243403
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1466092
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1466092
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
1000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
0
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
44897000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
41466000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-42064000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-37886000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
2834000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
3580000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3394000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5157000
CY2024Q3 us-gaap Revenues
Revenues
126000
CY2023Q3 us-gaap Revenues
Revenues
282000
us-gaap Revenues
Revenues
600000
us-gaap Revenues
Revenues
819000
CY2024Q3 us-gaap Cost Of Revenue
CostOfRevenue
82000
CY2023Q3 us-gaap Cost Of Revenue
CostOfRevenue
174000
us-gaap Cost Of Revenue
CostOfRevenue
359000
us-gaap Cost Of Revenue
CostOfRevenue
537000
CY2024Q3 us-gaap Gross Profit
GrossProfit
44000
CY2023Q3 us-gaap Gross Profit
GrossProfit
108000
us-gaap Gross Profit
GrossProfit
241000
us-gaap Gross Profit
GrossProfit
282000
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
422000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
337000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
980000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1295000
CY2024Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
234000
CY2023Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
480000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
946000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1390000
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
819000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1051000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2433000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3598000
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
1475000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
1868000
us-gaap Operating Expenses
OperatingExpenses
4359000
us-gaap Operating Expenses
OperatingExpenses
6283000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1431000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1760000
us-gaap Operating Income Loss
OperatingIncomeLoss
-4118000
us-gaap Operating Income Loss
OperatingIncomeLoss
-6001000
CY2024Q3 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
0
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
60000
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-0
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-60000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-1431000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-1760000
us-gaap Net Income Loss
NetIncomeLoss
-4178000
us-gaap Net Income Loss
NetIncomeLoss
-6001000
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.23
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.23
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.48
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.48
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.07
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.07
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-10.6
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-10.6
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6191127
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6191127
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1189821
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1189821
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3897938
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3897938
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
566228
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
566228
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
3630000
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
3412000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
195000
CY2023Q1 us-gaap Employee Benefits And Share Based Compensation Noncash
EmployeeBenefitsAndShareBasedCompensationNoncash
84000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-2116000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
5205000
CY2023Q2 us-gaap Employee Benefits And Share Based Compensation Noncash
EmployeeBenefitsAndShareBasedCompensationNoncash
81000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-2125000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
3161000
CY2023Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
4148000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
168000
CY2023Q3 us-gaap Employee Benefits And Share Based Compensation Noncash
EmployeeBenefitsAndShareBasedCompensationNoncash
48000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-1760000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
5765000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
3580000
CY2024Q1 us-gaap Employee Benefits And Share Based Compensation Noncash
EmployeeBenefitsAndShareBasedCompensationNoncash
54000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-1481000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
2153000
CY2024Q2 tivc Common Stock And Warrants Issued During Period Value New Issues
CommonStockAndWarrantsIssuedDuringPeriodValueNewIssues
3181000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
70000
CY2024Q2 us-gaap Employee Benefits And Share Based Compensation Noncash
EmployeeBenefitsAndShareBasedCompensationNoncash
54000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-1266000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
4192000
CY2024Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
15000
CY2024Q3 us-gaap Employee Benefits And Share Based Compensation Noncash
EmployeeBenefitsAndShareBasedCompensationNoncash
58000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-1431000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
2834000
us-gaap Profit Loss
ProfitLoss
-4178000
us-gaap Profit Loss
ProfitLoss
-6001000
us-gaap Share Based Compensation
ShareBasedCompensation
166000
us-gaap Share Based Compensation
ShareBasedCompensation
213000
us-gaap Depreciation
Depreciation
3000
us-gaap Depreciation
Depreciation
6000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
76000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
129000
tivc Inventory Allowances
InventoryAllowances
16000
tivc Bad Debt Expenses
BadDebtExpenses
5000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-160000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
43000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-9000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
65000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-93000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-8000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-380000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-685000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-268000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-184000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-96000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-115000
us-gaap Increase Decrease In Other Current Assets And Liabilities Net
IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet
-34000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4360000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6737000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
118000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-118000
tivc Proceeds From Issuance Of Common Stock And Warrants Net
ProceedsFromIssuanceOfCommonStockAndWarrantsNet
3266000
tivc Proceeds From Issuance Of Common Stock And Warrants Net
ProceedsFromIssuanceOfCommonStockAndWarrantsNet
8507000
tivc Offering Cost In Advance Of Sale Of Common Stock
OfferingCostInAdvanceOfSaleOfCommonStock
112000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3154000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
8507000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1206000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1652000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3395000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3517000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2189000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5169000
tivc Noncash Issuance Of Common Stock Warrant
NoncashIssuanceOfCommonStockWarrant
70000
tivc Noncash Issuance Of Common Stock Warrant
NoncashIssuanceOfCommonStockWarrant
363000
tivc Deferred Offering Costs Charged To Additional Paid In Capital
DeferredOfferingCostsChargedToAdditionalPaidInCapital
584000
tivc Write Off Of Rou Asset And Lease Liability
WriteOffOfRouAssetAndLeaseLiability
290000
us-gaap Net Income Loss
NetIncomeLoss
-4200000
us-gaap Net Income Loss
NetIncomeLoss
-6000000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-42100000
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2200000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4400000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6700000
CY2023Q3 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-100
CY2023Q3 tivc Stock Issued During Period Shares Fractional Shares
StockIssuedDuringPeriodSharesFractionalShares
0
CY2023Q3 us-gaap Stock Issued During Period Shares Reverse Stock Splits
StockIssuedDuringPeriodSharesReverseStockSplits
1
CY2023Q3 tivc Number Of Shares Included In Conversion Of Securities
NumberOfSharesIncludedInConversionOfSecurities
100
CY2023Q3 tivc Number Of Shares Included In Conversion Of Securities
NumberOfSharesIncludedInConversionOfSecurities
100
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual results could differ materially from those estimates. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate.</span></p>
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2200000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3400000
CY2024Q3 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0
CY2024Q3 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
0
CY2023Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
32000
CY2024Q3 us-gaap Deferred Offering Costs
DeferredOfferingCosts
112000
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2024Q3 us-gaap Deferred Revenue
DeferredRevenue
4000
CY2023Q4 us-gaap Deferred Revenue
DeferredRevenue
8000
CY2024Q3 tivc Sales Returns
SalesReturns
-20000
CY2023Q3 tivc Sales Returns
SalesReturns
-37000
tivc Sales Returns
SalesReturns
-67000
tivc Sales Returns
SalesReturns
-83000
CY2024Q3 us-gaap Revenues
Revenues
126000
CY2023Q3 us-gaap Revenues
Revenues
282000
us-gaap Revenues
Revenues
600000
us-gaap Revenues
Revenues
819000
tivc Product Warranty Limited Period
ProductWarrantyLimitedPeriod
P1Y
CY2024Q3 us-gaap Contract With Customer Refund Liability
ContractWithCustomerRefundLiability
10000
CY2023Q4 us-gaap Contract With Customer Refund Liability
ContractWithCustomerRefundLiability
52000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Concentration of Credit Risk and Other Risks and Uncertainties</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist of cash and cash equivalents and accounts receivable. Cash and cash equivalents include a checking account and a money market account held at one national financial institution in the United States. At times, such deposits may be in excess of insured limits. Management believes that the financial institution at which the Company holds its deposits is financially sound, and accordingly, minimal credit risk exists with respect to the financial institution. The Company has not experienced any losses on its deposits of cash and cash equivalents. As of each September 30, 2024 and December 31, 2023, the Company had cash and cash equivalents balances exceeding FDIC insured limits by </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company extends credit to customers in the normal course of business and performs credit evaluations of its customers. Concentrations of credit risk with respect to accounts receivable exist to the full extent of amounts presented in the financial statements.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the nine months ended September 30, 2024, the majority, or </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">82</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, of the Company’s sales have been to individual customers. In 2023, the majority, or </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">75</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, of the Company’s sales were to individual consumers. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> reseller customers whose accounts receivable balance totaled more than 10% or more of the Company’s total accounts receivable compared with one such customer at December 31, 2023 (</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">81</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%).</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the three months ended September 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> customer who individually accounted for 10% or more of the Company’s total revenue (</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">13</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%) compared to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> customer for the three months ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, (</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">40</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%).</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the nine months ended September 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> customer who individually accounted for 10% or more of the Company’s total revenue (</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%) compared to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> customer for the nine months ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%).</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The lingering negative impacts of the COVID-19 pandemic, the ongoing conflicts between Russia and Ukraine as well as Israel and Hamas, certain other macroeconomic factors including inflation, and rising interest rates, have contributed to economic uncertainty. Additionally, events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions or the financial services industry generally, or concerns or rumors about any events of these kinds or other similar risks, have in the past and may in the future lead to market-wide liquidity problems. Furthermore, it is possible that U.S. policy changes,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">including changes and uncertainty as a result of the upcoming U.S. presidential election, could increase market volatility in the coming months. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These factors, amongst other things, could result in further economic uncertainty and volatility in the capital markets in the near term, and could negatively affect our operations. We will continue to monitor material impacts on our business strategies and operating results.</span></p>
CY2024Q3 us-gaap Cash Uninsured Amount
CashUninsuredAmount
1900000
CY2023Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
3000000
CY2024Q3 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
2136000
CY2024Q3 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
2136000
CY2024Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
2136000
CY2024Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
2136000
CY2023Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
3243000
CY2023Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
3243000
CY2023Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
3243000
CY2023Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
3243000
CY2024Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
2100000
CY2023Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
3200000
CY2024Q3 tivc Fair Value Assets Level1 To Level2 Transfers Amount1
FairValueAssetsLevel1ToLevel2TransfersAmount1
0
CY2023Q4 tivc Fair Value Assets Level1 To Level2 Transfers Amount1
FairValueAssetsLevel1ToLevel2TransfersAmount1
0
CY2024Q3 tivc Fair Value Assets Level2 To Level1 Transfers Amount1
FairValueAssetsLevel2ToLevel1TransfersAmount1
0
CY2023Q4 tivc Fair Value Assets Level2 To Level1 Transfers Amount1
FairValueAssetsLevel2ToLevel1TransfersAmount1
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
CY2023 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
CY2024Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
481000
CY2023Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
752000
CY2024Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
5000
CY2023Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
0
CY2024Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
245000
CY2023Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
36000
CY2024Q3 us-gaap Inventory Gross
InventoryGross
731000
CY2023Q4 us-gaap Inventory Gross
InventoryGross
788000
CY2023Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
32000
CY2024Q3 us-gaap Inventory Net
InventoryNet
731000
CY2023Q4 us-gaap Inventory Net
InventoryNet
756000
CY2024Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
159000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
159000
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
40000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
37000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
119000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
122000
CY2024Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1000
CY2023Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
6000
CY2024Q3 us-gaap Area Of Land
AreaOfLand
9091
tivc Lessee Operating Leases Expiration Month And Year
LesseeOperatingLeasesExpirationMonthAndYear
2025-10
us-gaap Line Of Credit Facility Interest Rate During Period
LineOfCreditFacilityInterestRateDuringPeriod
0.06
CY2024Q3 tivc Operating Lease Termination Fee
OperatingLeaseTerminationFee
77000
CY2024Q3 us-gaap Security Deposit
SecurityDeposit
16000
us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
-60000
CY2024Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
0
us-gaap Operating Lease Cost
OperatingLeaseCost
84000
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
50000
us-gaap Operating Lease Cost
OperatingLeaseCost
151000
CY2024Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
0
us-gaap Operating Lease Payments
OperatingLeasePayments
87000
CY2023Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
51000
us-gaap Operating Lease Payments
OperatingLeasePayments
154000
tivc Monthly Rental Payments
MonthlyRentalPayments
1000
CY2024Q3 tivc Remaining Purchase Commitment Amount
RemainingPurchaseCommitmentAmount
231000
us-gaap Loss Contingency Loss In Period
LossContingencyLossInPeriod
0
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
40000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
218000
CY2024Q3 us-gaap Taxes Payable Current
TaxesPayableCurrent
0
CY2023Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
160000
CY2024Q3 tivc Other Accrued Research Study Costs
OtherAccruedResearchStudyCosts
102000
CY2023Q4 tivc Other Accrued Research Study Costs
OtherAccruedResearchStudyCosts
51000
CY2024Q3 tivc Other Accrued Liabilities Other Current
OtherAccruedLiabilitiesOtherCurrent
85000
CY2023Q4 tivc Other Accrued Liabilities Other Current
OtherAccruedLiabilitiesOtherCurrent
66000
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
227000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
495000
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6243403
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6243403
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1466092
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1466092
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-100
CY2023Q3 tivc Number Of Shares Included In Conversion Of Securities
NumberOfSharesIncludedInConversionOfSecurities
100
CY2023Q3 us-gaap Stock Issued During Period Shares Reverse Stock Splits
StockIssuedDuringPeriodSharesReverseStockSplits
1
CY2023Q3 tivc Stock Issued During Period Shares Fractional Shares
StockIssuedDuringPeriodSharesFractionalShares
0
CY2023Q3 tivc Cash Paid
CashPaid
0
CY2023Q3 tivc Other Consideration Paid
OtherConsiderationPaid
0
CY2023Q3 tivc Number Of Shares Included In Conversion Of Securities
NumberOfSharesIncludedInConversionOfSecurities
100
CY2023Q3 tivc Number Of Shares Included In Conversion Of Securities
NumberOfSharesIncludedInConversionOfSecurities
100
us-gaap Dividends Common Stock
DividendsCommonStock
0
CY2024Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
12022897
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
59497
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
66367
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
14661
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
928412
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
7190
CY2024Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
13017676
CY2023Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
81348
CY2023Q1 tivc Warrants Or Rights Fair Value Assumptions Method Used
WarrantsOrRightsFairValueAssumptionsMethodUsed
Black-Scholes options valuation model
CY2023Q1 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
195000
CY2023Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
168000
CY2024Q2 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
4710000
CY2024Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.85
CY2024Q2 tivc Warrants Or Rights Fair Value Assumptions Method Used
WarrantsOrRightsFairValueAssumptionsMethodUsed
Black-Scholes options valuation model
CY2024Q2 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
70000
CY2024Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
12022897
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2022 tivc Percentage Of Number Of Shares Added Each Year
PercentageOfNumberOfSharesAddedEachYear
0.05
CY2022Q4 tivc Percentage Of Number Of Shares Added Each Year
PercentageOfNumberOfSharesAddedEachYear
0.05
CY2023Q4 tivc Percentage Of Number Of Shares Added Each Year
PercentageOfNumberOfSharesAddedEachYear
0.05
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
14661
CY2023Q4 tivc Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price On Outstanding
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePriceOnOutstanding
6110
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
54000
tivc Share Based Compensation Arrangement By Share Based Payment Award Options Vested Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedExercisableNumber
3701
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
2294
tivc Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable For Canceled Or Expired In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableForCanceledOrExpiredInPeriod
781
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
66367
CY2024Q3 tivc Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price On Outstanding
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePriceOnOutstanding
9030
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
28.34
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
150.22
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y11M19D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y5M15D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
7500
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.34
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
3750
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
1.34
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
3750
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
1.34
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
58000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
48000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
166000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
213000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12089264
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
74699
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 tivc Rule10 B51 Arr Modified Flag
Rule10B51ArrModifiedFlag
false
CY2024Q3 tivc Non Rule10 B51 Arr Modified Flag
NonRule10B51ArrModifiedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-24-127072-index-headers.html Edgar Link pending
0000950170-24-127072-index.html Edgar Link pending
0000950170-24-127072.txt Edgar Link pending
0000950170-24-127072-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img41947313_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tivc-20240930.htm Edgar Link pending
tivc-20240930.xsd Edgar Link pending
tivc-ex31_1.htm Edgar Link pending
tivc-ex31_2.htm Edgar Link pending
tivc-ex32_1.htm Edgar Link pending
tivc-20240930_htm.xml Edgar Link completed